Longitudinal Development in Left Ventricular Volume, Mass and Function in Heart Transplant Recipients - Results From the NOCTET Trial

Allograft failure is an important cause of morbidity and mortality in heart transplant recipients. Several reasons for graft dysfunction: hypertension, kidney failure, vasculopathy and allograft hypertrophy, have been attributed to treatment with calcineurin inhibitors. Inhibitors of the mechanistic target of rapamycin (mTOR) may have a more favourable cardiovascular profile. We used data from the randomised, controlled NOCTET trial to assess if treatment with an mTOR-inhibitor attenuates allograft hypertrophy and prevents left ventricular dysfunction.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research